SIGA SIGA Technologies Inc. featured news, full reports, and detailed charts
SIGA Technologies Inc. (SIGA) Wrap Up:
SIGA Technologies, Inc., a biotechnology company, engages in the discovery, development, and commercialization of anti-infectives, antibiotics, and vaccines for the prevention and treatment of serious infectious diseases. The company focus on products for use in defense against biological warfare agents, such as smallpox, arenaviruses (hemorrhagic fevers), and other category A viral agents. Its lead product, ST-246, is an orally administered anti-viral drug that targets orthopox viruses. The company?s product candidates also include ST-294 and ST-193, which demonstrates antiviral activity in cell culture assays against arenavirus pathogens; and ST-669, a broad spectrum antiviral candidate, for various viruses in the Poxviridae, Filoviridae, Bunyaviridae, Arenaviridae, Flaviviridae, Togaviridae, Retroviridae, and Picornaviridae families. In addition, it also has four drug series in the pre-clinical development stage, including ST-610 and ST-148 for dengue virus of the genus Flavivirus. The company has license agreements, collaborative research arrangements, and contracts with National Institutes of Health and the United States Air Force. SIGA Technologies was founded in 1995 and is headquartered in New York, New York.www.siga.com
43 Employees
Founded in 1995
SIGA Technologies Inc. (SIGA:NASDAQ)
LAST $7.20 USD
CHANGE TODAY +0.36 5.26%
VOLUME 820.6K
As of 4:00 PM 11/20/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of SIGA Technologies Inc. (SIGA)
|
OPEN
$6.79
|
PREVIOUS CLOSE
$6.84
|
|
|
DAY HIGH
$7.33
|
DAY LOW
$6.76
|
|
|
52 WEEK HIGH
06/30/09 - $8.88
|
52 WEEK LOW
11/20/08 - $1.94
|
|
|
MARKET CAP
275.9M
|
AVERAGE VOLUME 3 mo
200.1K
|
|
|
DILUTED EPS TTM
$-0.56
|
SHARES OUTSTANDING
38.3M
|
|
|
SIGA Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
SIGA Top Compensated Officers
Dr. Eric A. Rose M.D.
Executive Chairman, Chief Executive Officer a...
Age: 57
Total Annual Compensation: $400.0K
Mrs. Ayelet Dugary
Chief Financial Officer, Principal Accounting...
Age: 41
Total Annual Compensation: $220.0K
Dr. Dennis E. Hruby Ph.D.
Chief Scientific Officer and Vice President
Age: 56
Total Annual Compensation: $375.0K
Executives, Board Directors
Compensation as of Fiscal Year 2008.
Key developments for SIGA Technologies Inc. (SIGA)
SIGA Technologies Inc. Reports Operating Results for the Third Quarter and Nine Months Ended September 30, 2009
11/9/2009
SIGA Technologies Inc. reported operating results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported that operating loss was $2.6 million up approximately $485,000 from the loss incurred in the prior year period, with the increase mainly driven by higher G&A costs. Net loss per share for the three-month periods ending September 30, 2009 and 2008 was $0.04 and $0.09, respectively. The decline in net loss per share primarily results from gains recorded during the third quarter in 2009 due to the decline in fair market value of common stock warrants classified as liabilities on its balance sheet. The company recognized revenues of $3.9 million for the quarter. The increase from revenues recognized during the same period in the prior year was mainly driven by the continued research and development activities supporting its ST-246(R) grants and contracts. For the nine months ended September 30, 2009, the company reported revenue of $9.9 million, an increase of approximately $4.3 million, or 43%, as compared to $5.6 million reported for the nine months ended September 30, 2008. For the nine months ended September 30, 2009, the company recorded $8.9 million from grants and contracts supporting the development of its lead drug candidate, ST-246. Revenue from grants and contracts supporting these programs during the same period in 2008 was $4.2 million. Operating loss for the nine-month period was $8.1 million, up $1.9 million from the prior-year nine-month period loss of $6.2 million. Net loss per share for the nine-month periods ending September 30, 2009 and 2008 were $0.51 and $0.20, respectively.
SIGA Technologies Inc. expected to Report Fiscal Year 2009 Results on March 1, 2010. This event was calculated by Capital IQ (Created on November 9, 2009).
11/9/2009
SIGA Technologies Inc. expected to Report Fiscal Year 2009 Results on March 1, 2010. This event was calculated by Capital IQ (Created on November 9, 2009).
SIGA Presents Update on ST-246 Development to the World Health Organization
11/5/2009
SIGA Technologies Inc. presented its progress in developing its lead drug candidate, ST-246, an antiviral for smallpox and other orthopoxviruses, to the World Health Organization (WHO) Advisory Committee on Variola Virus Research on November 4, 2009 in Geneva, Switzerland. Since the last presentation to the Advisory Committee on Variola Virus Research, SIGA has achieved a number of important milestones with ST-246, including the completion of nonclinical toxicology studies that support safety in humans and the successful treatment of a patient suffering from complications due to exposure to a live vaccinia-vectored rabies vaccine.
SIGA Competitors
| Company | Last | Change | |
| No competitor information is available for SIGA. | |||
| Market data is delayed at least 20 minutes. | |||
Industry Analysis
| Valuation | SIGA | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 22.0x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 22.2x |
|
|
SIGA |
||
|
SIGA transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent News About SIGA Technologies Inc.
More news for SIGA
$1.6 Million NIH Cooperative Agreement Supports SIGA Broad Spectrum Antiviral Research
NEW YORK, Sept. 29, 2009 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA - News), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced the receipt of a $1.6 million research project cooperative agreement from the National Institutes of Health ("NIH") to accelerate the development of its broad-spectrum antiviral candidates. Funds for the agreement have been made available through the American Recovery and Reinvestment Act ("ARRA") of 2009, which supports projects that will stimulate the economy, create or retain jobs, and have the potential for making scientific progress within two years of funding. Dr. Robert Allen, principal investigator at SIGA for this grant, commented, "Working to develop a safe and effective lead compound and advancing this project into a clinical trial is our goal. These funds will support our efforts to find targets of identified broad-spectrum compounds." "We are grateful for the government's continued commitment to funding our broad spectrum antiviral program. The funding we will receive as part of the stimulus plan, combined with another government contract that we are currently negotiating, is important to the success of this program," said Dr. Eric Rose, SIGA's Chief Executive Officer. Broad-spectrum antiviral candidates, including ST-669, were discovered as part of a high-throughput screening campaign conducted against multiple viruses in the Bunyavirus family. These compounds demon...Click here to read the whole Article (external link)
SIGA TECHNOLOGIES INC Files SEC form 8-K, Unregistered Sale of Equity Securities
Item 3.02 Unregistered Sales of Equity Securities. On August 25, 2009, SIGA Technologies, Inc., a Delaware corporation ("SIGA"), notified MacAndrews & Forbes LLC (the "Investor") of its intention to exercise its right to cause the Investor to invest $1,000,000 in SIGA pursuant to the terms of the letter agreement between SIGA and the Investor dated June 18, 2008, as amended April 29, 2009 (the "Letter Agreement"), the consummation of such investment being subject to the negotiation and execution of mutually acceptable definitive documentation. On September 17, 2009, the Investor funded $1,000,000 to SIGA, pursuant to the terms of the Letter Agreement, following the execution of definitive documentation (including, without limitation, documentation providing the Investor with certain registration rights with respect to the Shares (as defined below) and the shares of common stock underlying the Consideration Warrants (as defined below)) by and between SIGA and the Investor on such date. SIGA intends to use the proceeds of the investment for general corporate purposes. On September 17, 2009, in exchange for the investment in SIGA by the Investor described above, SIGA issued to the Investor 326,797 shares of SIGA common stock (the "Shares") at a per share price of $3.06. In connection with the foregoing, on even date therewith, SIGA issued certain warrants (the "Consideration Warrants") to the Investor to purchase 130,719 shares of SIGA common stock at an exercise price of $3.519 per share. The Consideration Warrants will be exercisable until September 17, 2013. The sale of the Shares and Consideration Warrants has not been registered under the Securities Act of 1933, as amended (the "Securities Act"). The Shares and Consideration Warrants were sold to the Investor in reliance upon exemptions from registration under Section 4(2) of the Securities Act and Rule 506 of Regulation D promulgated thereunder. The issuanc...Click here to read the whole Article (external link)
SIGA Technologies Files $100 Million Shelf Registration
NEW YORK, Oct. 30, 2009 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA - News), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, announced the filing with the Securities and Exchange Commission (the "SEC") of a shelf registration statement on Form S-3 with respect to its common stock and warrants to purchase common stock. After the registration statement is declared effective by the SEC, SIGA will have the flexibility to raise funds up to an aggregate of $100 million and issue registered common stock and warrants to purchase common stock, from time to time, in one or more separate offerings with the size, price and terms to be determined at the time of issuance. SIGA currently intends to use the net proceeds from any sale of securities for general corporate purposes, including development of its product candidates, the acquisition or in-license of technologies, products or businesses, working capital and capital expenditures. SIGA may set forth additional information on the use of proceeds from any sale of securities in a prospectus supplement relating to the specific primary offering. A registration statement relating to the securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell securities, or the solicitation of an offer to buy se...Click here to read the whole Article (external link)
SIGA Presents Update on ST-246(R) Development to the World Health Organization
NEW YORK, Nov. 5, 2009 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA - News), a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, today announced that Dr. Dennis E. Hruby, SIGA's Chief Scientific Officer, presented SIGA's progress in developing its lead drug candidate, ST-246, an antiviral for smallpox and other orthopoxviruses, to the World Health Organization (WHO) Advisory Committee on Variola Virus Research on November 4, 2009 in Geneva, Switzerland. Dr. Hruby commented on the presentation: "We are very pleased to once again provide an update on our progress before the World Health Organization. Since our last presentation to the Advisory Committee on Variola Virus Research, SIGA has achieved a number of important milestones with ST-246, including the completion of nonclinical toxicology studies that support safety in humans and the successful treatment of a patient suffering from complications due to exposure to a live vaccinia-vectored rabies vaccine." Dr. Hruby continued, "This meeting also comes at a very important time for SIGA, as an acquisition of ST-246 is currently being considered for the National Strategic Stockpile following our response to a request for proposal from the Department of Health and Human Services that was issued in March of 2009." About SIGA Technologies, Inc. SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of n...Click here to read the whole Article (external link)
SIGA Technologies to Discuss Third Quarter 2009 Results of Operations on November 9, 2009
SIGA Technologies to Discuss Third Quarter 2009 Results of Operations on November 9, 2009 - Yahoo! Finance.gnwlistitemmarginbottom {margin-bottom: 10.0px} .gnwtablebottommargin {margin-bottom: 10.0px} .gnwcellpaddingleft0 {padding-left: 0.0px} .gnwverticalaligntop {vertical-align: top} .gnwtextaligncenter {text-align: center} .gnwcellparagraphmargin {margin-bottom: 0px; margin-top: 0px} .gnwverticalalignbottom {vertical-align: bottom} .gnwwhitespacenowrap {white-space: nowrap} .gnwtextalignright {text-align: right} .gnwcellpaddingright0 {padding-right: 0.0px} .gnwunderlinestyle {text-decoration: underline} .gnwtextalignleft {text-align: left} .gnw_heading {font: 16px Arial; text-align: center} .gnw_subhead {font: 12px Arial; text-align: center} .gnw_colhead {font: 12px Arial; text-align: center} .gnw_colhead_uline {font: 12px Arial; text-align: center; border-bottom: solid black 1.0pt;} .gnw_colhead_dline {font: 12px Arial; text-align: center; border-bottom: double black 2.5pt;} .gnw_label {font: 12px Arial; vertical-align: bottom; text-align: left } .gnw_label_uline {font: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: solid black 1.0pt;} .gnw_label_uline_i10 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i15 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i20 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i25 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i30 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_dline {font: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: double black 2.5pt;} .gnw_label_i10 {font: 12px Arial; vertical-align: bottom; text-align: left; padding-left: 10.0px;} .gnw_label_i15 {font: 12px Arial; vertical-align: bottom; t...Click here to read the whole Article (external link)
Q3 2009 SIGA Technologies Earnings Release - Time Not Supplied
Earnings Announcements for Monday, November 9CompanySymbolTimeConferenceCall4Kids EntertainmentKDEBefore Market OpenAbatixABIX.PKAfter Market CloseAbraxas PetroleumAXASAfter Market CloseListenACADIA PHARMACEUTICALS INCACADAfter Market CloseADVANCED BATTERY TECHNOLOG INCABATAfter Market CloseAdvanced PhotonixAPIAfter Market CloseListenAdvanta CorporationADVNATime Not SuppliedAdvocatAVCAAfter Market CloseListenAlbany Molecular ResearchAMRIBefore Market OpenAlesco Financial Inc.AFNAfter Market CloseAlexza Pharmaceuticals Inc.ALXAAfter Market CloseListenAlliance One International, Inc.AOIAfter Market CloseAllianz SEAZSEY.PK01:30 am ETListenALLION HEALTHCARE INCALLITime Not SuppliedALPHATEC HOLDINGS INCATECTime Not SuppliedAmerican CareSource Holdings, Inc.ANCIAfter Market CloseA...Click here to read the whole Article (external link)
SIGA TECHNOLOGIES INC Financials
PERIOD ENDING30-Sep-0930-Jun-0931-Mar-0931-Dec-08Total Revenue3,922 4,009 1,926 2,489 Cost of Revenue - - - - Gross Profit3,922 4,009 1,926 2,489 Operating ExpensesResearch Development4,828 4,713 2,697 3,423 Selling General and Administrative1,907 1,802 2,060 1,613 Non Recurring(194)84 109 - Others - - - - Total Operating Expenses - - - - Operating Income or Loss(2,619)(2,590)(2,940)(2,547)Income from Continuing OperationsTotal Other Income/Expenses Net1,191 (7,763)(3,944)976 Earnings Before Interest And Taxes(1,429)(10,353)(6,885)(1,571)Interest Expense - - - - Income Before Tax(1,429)(10,353)(6,885)(1,571)Income Tax Expense - - - - Minority Interest - - - - Net Income From Continuing Ops(1,429)(10,353)(6,885)(1,571)Non-recurring EventsDiscontinued Operations - - - - Extraordinary Items - - - - Effect Of Accounting Changes - - - - ...Click here to read the whole Article (external link)
SIGA TECHNOLOGIES INC Files SEC form 10-Q, Quarterly Report
Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations. The following discussion should be read in conjunction with our consolidated financial statements and notes to those statements and other financial information appearing elsewhere in this Quarterly Report. In addition to historical information, the following discussion and other parts of this Quarterly Report contain forward-looking information that involves risks and uncertainties. Overview Since our inception in December 1995, SIGA has pursued the research, development and commercialization of novel products for the prevention and treatment of serious infectious diseases, including products for use in the defense against biological warfare agents such as smallpox and Arenaviruses. Our lead product, ST-246®, is an orally administered antiviral drug that targets orthopox viruses. In December 2005, the U.S. Food and Drug Administration (the "FDA") accepted our Investigational New Drug ("IND") application for ST-246® and granted the program "Fast-Track" status. In December 2006, the FDA granted Orphan Drug designation to ST-246® for the prevention and treatment of smallpox. In May 2009, we submitted a response to a Request for Proposal ("RFP") issued by the U.S. Biomedical Research and Development Agency ("BARDA") with respect to the purchase of 1.7 million courses of a smallpox antiviral (the "BARDA Smallpox RFP"), and, in June 2009, BARDA informed us that our response to the BARDA Smallpox RFP was deemed technically acceptable and in the competitive range. There can be no assurance that SIGA or any other company will receive an award pursuant to this RFP. Further, any award on this RFP would be subject to negotiation of final contract terms and specifications; thus, the final terms under any contract with BARDA may be materially different than those indicated in the RFP. Our anti-viral programs are desi...Click here to read the whole Article (external link)
SIGA Technologies Reports Operating Results for the Third Quarter of 2009
NEW YORK, Nov. 9, 2009 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA - News), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced its results of operations for the third quarter of 2009. The Company recognized revenues of $3.9 million and $9.9 million for the three and nine months ended September 30, 2009, respectively. The increase from revenues recognized during the same periods in the prior year was mainly driven by the continued research and development activities supporting our ST-246(R) grants and contracts. Dr. Eric Rose, SIGA's Chairman and CEO, commented, "Our efforts to transition SIGA to a successful commercial-stage drug company continued to advance during the quarter. Nonclinical toxicology studies needed to satisfy a future New Drug Application for ST-246 were completed, and we are currently pursuing commercial validation and clinical safety studies. These developments, as well as infrastructure and compliance activities we carried out, support our pursuit of a BARDA contract." Financial Overview Operating loss for the quarter was $2.6 million, up approximately $485 thousand from the loss incurred in the prior year period, with the increase mainly driven by higher G&A costs. Net loss per share for the three-month periods ending September 30, 2009 and 2008 was $0.04 and $0.09, respectively. The decline in net loss per share primarily results from gains recorded during the third...Click here to read the whole Article (external link)
Semi-Annual Changes to the NASDAQ Biotechnology Index
NEW YORK, Nov. 13, 2009 (GLOBE NEWSWIRE) -- The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ - News) announced today the results of the semi-annual re-ranking of the NASDAQ Biotechnology Index(R) (Nasdaq:NBI - News), which will become effective with the market open on Monday, November 23, 2009. The re-ranking will result in the following eight securities being added to the Index: China Sky One Medical, Inc. (Nasdaq:CSKI - News), Hi-Tech Pharmacal Co., Inc. (Nasdaq:HITK - News), Poniard Pharmaceuticals, Inc. (Nasdaq:...Click here to read the whole Article (external link)
Would you like to leave a comment about SIGA Technologies Inc. SIGA
Find out what social network information about SIGA Technologies Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides SIGA Technologies Inc. there is more great information available at Realpennies.com